Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in STRASBOURG, Alsace – page 60

977 clinical trials in STRASBOURG, Alsace, France across 6 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
STRASBOURG, Alsace at a glance
977
clinical trials
  • Research sites6
Type of trial
Recruitment status
Quick filters

977 trials in STRASBOURG, Alsace

Open in trial search

Cholangitis sclerosing

Not recruiting

Study on Bezafibrate for Patients with Primary Sclerosing Cholangitis and Persistent Cholestasis Despite Ursodeoxycholic Acid Therapy

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bezafibrate
  • Sponsor:Assistance Publique Hopitaux De Paris

Human herpesvirus 6 encephalitis

Not recruiting

Study on Dexamethasone for Patients with Herpes Simplex Virus Encephalitis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Centre Hospitalier Universitaire Grenoble Alpes

Dry age-related macular degeneration

Not recruiting

Study on Long-Term Safety and Effects of Pegcetacoplan for Patients with Geographic Atrophy from Age-Related Macular Degeneration

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Pegcetacoplan
  • Sponsor:Apellis Pharmaceuticals Inc.

Breast cancer female

Not recruiting

Study on Chemotherapy and Hormone Therapy for Women Over 70 with ER-Positive, HER2-Negative Breast Cancer Using Cyclophosphamide and Drug Combination

Registered drugNo placebo
Countries:FranceFrance
  • Participants:65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Unicancer

Interstitial lung disease

Not recruiting

Study on BI 1015550 for Improving Lung Function in Patients with Progressive Fibrosing Interstitial Lung Diseases

Investigational
Countries:FranceFrance
  • Participants:65+ years
  • Substances:Bi 1015550
  • Sponsor:Boehringer Ingelheim Espana S.A.

Non-small cell lung cancer

Not recruiting

Study on the Safety and Effectiveness of Acasunlimab and Pembrolizumab for Patients with Recurrent Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Acasunlimab
  • Sponsor:Genmab A/S

Pulmonary arterial hypertension

Not recruiting

Study of Sotatercept for Newly Diagnosed Intermediate- and High-risk Pulmonary Arterial Hypertension Patients

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Sotatercept
  • Sponsor:Acceleron Pharma Inc.

Study on Early vs. Late Epoetin Alfa Treatment for Adults with Low-Risk MDS and Anemia Not Requiring Blood Transfusions

Not recruiting
Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Epoetin Alfa
  • Sponsor:Groupe Francophone Des Myelodysplasies

Pulmonary arterial hypertension

Not recruiting

Long-term Study of Sotatercept for Adults with Pulmonary Arterial Hypertension (PAH)

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Sotatercept
  • Sponsor:Acceleron Pharma Inc.

Triple negative breast cancer+1

Not recruiting

Study on the Effects of Atezolizumab, Trastuzumab, and Pertuzumab in Patients with Early-Stage Triple-Negative or HER2+ Breast Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Institut Gustave Roussy

Breast cancer+1

Not recruiting

Study Comparing Chemotherapy and Abemaciclib with Hormone Therapy for Patients with ER+ HER2- Metastatic Breast Cancer with Visceral Involvement

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Unicancer

Metastatic renal cell carcinoma

Not recruiting

Study of Axitinib and Pembrolizumab for Patients with Advanced or Metastatic Papillary Renal Cell Carcinoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Axitinib
  • Sponsor:Centre Leon Berard

Other cities in France

The busiest research cities in the country

All 380 cities in France

Clinical research in STRASBOURG, Alsace

What the registry says about research in the country

01 Oncology Research

Advanced studies focusing on head and neck cancers, bladder cancer, and multiple myeloma. Novel therapeutic approaches combining immunotherapy with established treatments are being evaluated for improved patient outcomes.

  • EGFR-targeted therapies for head and neck cancer
  • Non-muscle invasive bladder cancer treatment
  • Multiple myeloma consolidation therapy

Innovative combination therapies are being tested to enhance treatment efficacy while maintaining patient safety.

02 Neurological Disorders

Comprehensive research into multiple sclerosis, essential tremor, and ADHD. Studies are evaluating both new and existing medications for improved symptom management and disease control.

  • Multiple sclerosis treatment strategies
  • Essential tremor therapeutic interventions
  • ADHD neural mechanism studies

Advanced neuroimaging techniques are being utilized to understand treatment effects on brain circuits.

03 Autoimmune Conditions

Investigating new treatments for Crohn's disease, Sjögren's Syndrome, and Myasthenia Gravis. Research focuses on innovative therapeutic approaches including microbiota transplantation and targeted immunotherapies.

  • Fecal microbiota transplantation studies
  • Novel antibody treatments
  • Immunomodulatory therapies

These trials aim to improve disease management and patient quality of life through targeted interventions.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.